First-In-Human Study Evaluating a Novel Catheter Device in Subjects With Treatment-Resistant Hypertension
The carotid body is located at the bifurcation of the internal and external carotid arteries. It is a chemoreceptor that plays a role in the sympathetic nervous system and in the development and maintenance of hypertension. Hypertension is a major cardiovascular risk factor and is associated with coronary artery disease, stroke, chronic kidney disease, and heart failure. The objective of this study is to assess the effectiveness and safety of a catheter-based system to ablate the carotid body and reduce blood pressure (BP) in patients with resistant hypertension and to confirm sustainability of the treatment benefits long-term as seen following surgical CB removal.
Full Title of Study: “First-In-Human Study for Ultrasound Based Endovascular Carotid Body Ablation in Subjects With Treatment-Resistant Hypertension: A Safety and Feasibility Study”
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: August 2018
- Device: Catheter-Based Carotid Body Ablation
- The Cibiem Transvenous Ultrasound System (CTUS) is a catheter based device delivering ultrasound energy to ablate the carotid body. The procedure is done via a percutaneous insertion of the CTUS and advancement through the femoral vein to the jugular vein in subjects with difficult to control hypertension. The procedure duration is expected to range between 60 to 90 minutes and is performed under fluoroscopic and ultrasound image guidance.
Arms, Groups and Cohorts
- Experimental: Catheter-Based Carotid Body Ablation
- All subjects undergo catheter-based ablation of the carotid body using the Cibiem Transvenous Ultrasound System (CTUS).
Clinical Trial Outcome Measures
- Safety as assessed by incidence of major adverse events
- Time Frame: From procedure to one month post-procedure
- Safety assessed as the combined rate of major adverse events defined as all-causes of death, hospitalization for hypertensive crisis not related to confirmed non-adherence with anti-hypertensive medications, and any device or procedure-related serious adverse event.
- Mean reduction in 24-hour ambulatory systolic and diastolic blood pressure
- Time Frame: Baseline versus six months post-procedure
- Composite rate of major adverse events
- Time Frame: At 6, 12, 18, and 24 months post-procedure
- Safety assessed as the combined rate of major adverse events defined as all-causes of death and hospitalization for hypertensive crisis not related to confirmed non-adherence with anti-hypertensive medications
- Mean reduction in office systolic and diastolic blood pressure, and home systolic and diastolic blood pressure
- Time Frame: Baseline versus 3, 6, 12, 18, and 24 months
- Proportion of subjects with controlled blood pressure at 6, 12, 18, and 24 months post-procedure
- Time Frame: At 6, 12, 18, and 24 months
- Controlled blood pressure is defined as office blood pressure <140/90 mmHg, mean 24-hr ABP <130/80 mmHg, daytime ABP <135/85 mmHg, and mean nighttime ABP <120/70 mmHg
- Ventricular morphometric improvements from cardiac MRI measurements
- Time Frame: Screening versus 12 and 24 months
Participating in This Clinical Trial
- Mean office SBP ≥160 mmHg and DBP ≥90 mmHg during screen-in period – Mean daytime systolic ABPM ≥135 mmHg during screen-in period – Adherent to a stable drug regimen of three (3) or more anti-hypertensive medications of different classes (including one (1) diuretic), with no medication changes expected for at least six (6) months post-procedure – No change in anti-hypertensive drug prescription (dose, number of medications, or class of medication) for at least six (6) weeks prior to enrollment – Negative pregnancy test for women of child-bearing age – Willingness and able to comply with follow-up requirements – Signed informed consent Exclusion Criteria:
- Secondary causes of hypertension – Calculated eGFR <30mL/min/1.73m2 – History of repeated episodes of hypoglycemic unawareness – Morbid obesity, defined as Body Mass Index >40 kg/m2 – Severe obstructive sleep apnea (AHI > 35/hr.) – Pacemaker and/or implantable defibrillators – History of transient ischemic accident or cerebrovascular accident during six (6) months prior to screening – History of acute heart failure, congestive heart failure (NYHA class III-IV), myocardial infarction, unstable angina, coronary bypass or coronary angioplasty during six (6) months prior to screening – History of ipsilateral carotid endarterectomy treatment or ipsilateral carotid artery stenting
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- Cibiem, Inc.
- Provider of Information About this Clinical Study
- Overall Official(s)
- Markus Schlaich, Professor, Principal Investigator, Royal Perth Hospital
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.